Literature DB >> 8343182

Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterization and clinical correlations.

A H Mulder1, G Horst, M A van Leeuwen, P C Limburg, C G Kallenberg.   

Abstract

OBJECTIVE: To study the prevalence, interrelationships, and target antigens of antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis (RA) and to relate their presence to disease duration and to the occurrence of extraarticular manifestations, including vasculitis.
METHODS: Sera from 94 patients with RA (31 with recent-onset disease, 35 with longstanding disease but without extraarticular manifestations, and 28 with extraarticular disease) were studied for the presence of ANCA by indirect immunofluorescence. All sera were tested by enzyme-linked immunosorbent assay (ELISA) for the presence of antibodies to proteinase 3, myeloperoxidase (MPO), elastase, lactoferrin (LF), and cathepsin G (CG), and by Western blotting for antibodies to neutrophil proteins.
RESULTS: Seventy percent of the 94 sera showed staining of the nuclei of ethanol-fixed neutrophils; 32% of the 94 were proven to have ANCA, as manifested by their cytoplasmic staining pattern on paraformaldehyde-fixed neutrophils. In the ELISA, 19 sera reacted with LF, 1 with MPO, and 1 with CG. By Western blotting, 21 sera reacted with LF, and 15 reacted with previously unknown polypeptides (7 sera with a 67/66-kd doublet and 8 with a 63/54-kd doublet). Neither of these antibodies was associated with a particular subset of the disease, but the prevalence of the antibodies tended to increase among patients with longstanding disease.
CONCLUSION: ANCA in RA patients are directed toward diverse cytoplasmic antigens of the neutrophil, in particular, LF and other, not yet fully characterized polypeptides. The antibodies are not a marker for a disease subset, but are probably a corollary of chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8343182     DOI: 10.1002/art.1780360805

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

Review 1.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  Amphipathic variable region heavy chain peptides derived from monoclonal human Wegener's anti-PR3 antibodies stimulate lymphocytes from patients with Wegener's granulomatosis and microscopic polyangiitis.

Authors:  E Peen; C Malone; C Myers; R C Williams; A B Peck; E Csernok; W L Gross; R Staud
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

Review 3.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

Review 4.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 5.  Pulmonary vasculitis.

Authors:  Kevin K Brown
Journal:  Proc Am Thorac Soc       Date:  2006

6.  Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations.

Authors:  Irena Manolova; Maria Dantcheva
Journal:  Rheumatol Int       Date:  2004-11-11       Impact factor: 2.631

Review 7.  The diversity of perinuclear antineutrophil cytoplasmic antibodies (pANCA) antigens.

Authors:  A Wiik; L Stummann; L Kjeldsen; N Borregaard; S Ullman; S Jacobsen; P Halberg
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

8.  Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates.

Authors:  Domenico Caccavo; Amelia Rigon; Antonio Picardi; Sara Galluzzo; Marta Vadacca; Giovanni Maria Ferri; Antonio Amoroso; Antonella Afeltra
Journal:  Clin Rheumatol       Date:  2004-12-09       Impact factor: 2.980

9.  Anti-neutrophil cytoplasm antibodies (ANCA) in rheumatoid arthritis: relationship to HLA-DR phenotypes, rheumatoid factor, anti-nuclear antibodies and disease severity.

Authors:  E Röther; D Metzger; B Lang; I Melchers; H H Peter
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

Review 10.  Update on autoantibodies in rheumatoid arthritis.

Authors:  S Louis Bridges
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.